🇺🇸 FDA
Patent

US 10508122

Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof

granted A61PA61P25/00A61P35/00

Quick answer

US patent 10508122 (Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof) held by The Regents of the University of Colorado, a Body Corporate expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Dec 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P25/00, A61P35/00, A61P37/00, A61P37/02